ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
As GlaxoSmithKline retrenches its early-stage research, it is shedding several dozen clinical development jobs at its R&D site in Research Triangle Park, N.C. In all, roughly 50 jobs in the U.S. neuroscience unit are being shed. The British drug firm has been paring back internal R&D as it expands its network of external partnerships. Last year, GSK said it would end or cut back research at six sites worldwide. It also decided to end research in certain neuroscience areas, including depression and pain.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X